期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

维甲酸固体脂质纳米粒冷冻干燥工艺研究 被引量：8

Lyophilization of Solid Lipid Nanoparticles Loaded with All-trans Retinoic Acid
暂未订购
导出
摘要 选用不同辅料作为冻干保护剂,制备维甲酸固体脂质纳米粒冻干品,并考察不同制品的外观、粒径、包封率。以冻干品外观、再分散后的粒径和包封率为评价指标,筛选保护剂的优化处方。结果表明,选择蔗糖、蔗糖+海藻糖、甘露醇+海藻糖、甘露醇+蔗糖为冻干保护剂,冻干纳米粒再分散后粒径减小,包封率与冻干前相比有所降低,含海藻糖处方可大大加快纳米粒的再分散速率,4℃和20℃放置3个月稳定性良好。 The lyophilized solid lipid nanoparticles （SLN） loaded with all-trans retinoic acid were prepared using different cryoprotectants. The effects of different cryoprotectants on the properties of SLN such as appearance, the mean particle size and encapsulation efficiency after lyophilization and reconstitution were investigated to opfimize the combination of cryoprotectants. The results showed that using sucrose alone or the combination of different cryoprotectants e.g. sucrose and trehalose, mannitol and trehalose or mannitol and sucrose, the mean size and the encapsulation efficiency of the lyophilized products after reconstitution decreased by comparison with those of the products before lyophilization. Trehalose formulation offered a rapid hydration velocity. The froze-drill SLN displayed good stability after storage for 3 months at 4℃ and 20℃.
作者 胡连栋 唐星 崔福德
机构地区 河北大学药学院 沈阳药科大学药学院
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2007年第1期22-26,共5页 Chinese Journal of Pharmaceuticals
关键词 维甲酸 固体脂质纳米粒 冻干保护剂 冷冻干燥 all-trans retinoic acid solid lipid nanoparticles （SLN） cryoprotectants iyophilization
分类号 R944.9 [医药卫生—药剂学]
  • 相关文献

参考文献12

  • 1Mehnert W,Mader K.Solid lipid nanoparticles:production,characterization and applications[J].Adv Drug Deliv Rev,2001,47(2-3):165-196.
  • 2Allison SD,Manning MC,Randolph TW,et al.Optimization of storage stability of lyophilized actin using combinations of disaccharides and dextran[J].J Pharm Sci,2000,89 (2):199-214.
  • 3Imamura K,Fukushima A,Sakaura K,et al.Water sorption and glass transition behaviors of freeze-dried sucrose-dextran mixtures[J].JPharm Sci,2002,91 (10):2175-2181.
  • 4Liao YH,Brown MB,Martin GP.Investigation of the stabilisation of freeze-dried lysozyme and the physical properties of the formulations[J].Eur J Pharm Biopharm,2004,58 (1):15-24.
  • 5Zhang JA,Xuan T,Parmar M,et al.Development and characterization of a novel liposome-based formulation of SN-38[J].IntJPharm,2004,270 (1-2):93-107.
  • 6Schwarz C,Mehnert W.Freeze-drying of drug-free and drugloaded solid lipid nanoparticles (SLN)[J].Int J Pharm,1997,157(2):171-179.
  • 7Tsinontides SC,Rajniak P,Pham D,et al.Freeze drying-principles and practice for successful scale-up to manufacturing[J].IntJPharm,2004,280 (1-2):1-16.
  • 8Gloger O,Witthohn K,Muller BW.Lyoprotection of aviscumine with low molecular weight dextrans[J].Int J Pharm,2003,260 (1):59-68.
  • 9Franks F.Freeze-drying of bioproducts:putting principles into practice[J].Eur J Pharm Biopharm,1998,45 (3):221-229.
  • 10胡连栋,唐星,崔福德.全反式维甲酸固体脂质纳米粒的制备及体内外评价[J].药学学报,2005,40(1):71-75. 被引量：20

二级参考文献12

  • 1Muller RH, Karsten M, Sven G. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state or the art [J]. Eur J Pharm Biopharm, 2000,50(1) :161 -77.
  • 2Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery. Ⅱ. Drug incorporation and physicochemical characterization [ J ]. J Microencapsulation, 1999,16( 2 ) :205 - 213.
  • 3Yang SC, Lu LF, Cai Y, et al. Body distribution in mice of intravenously injected camptothecin solid lipid nanoarpticles and targeting effect on brain [ J ]. J Control Release, 1999,59 ( 3 ) :299 - 307.
  • 4Cavalli R, Fundaro A, Bargoni A, et al. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN) [J]. Pharmcol Res, 1999,44 (3) :281 -286.
  • 5Runge S, Mehnert W, Muller RH. SLN (solid lipid nanoparticles ) a novel formulation for the oral administration of drugs [ J]. Eur J Pharm Sci, 1996,4 ( Suppl 1 ): S132.
  • 6Yang S, Zhu JB, Lu Y, et al. Body distribution of camptothecin solid lipid nanoparticles after oral administration [ J ]. Pharm Res, 1999,16 (5) :751 - 757.
  • 7Mehnert W, Mader K. Solid lipid nanoparticles production, characterization and applications [ J ]. Adv Drug Deliv Rev, 2001,47 (2 - 3 ): 165 - 196.
  • 8Regazzi MB, Iacona I, Gervasutti C, et al. Clinical pharmacokinetics of tretinoin [ J ]. Clin Pharmacokinet, 1997,32(5 ) :382 -402.
  • 9Komatsu H, Kitajima A, Okada S. Pharmaceutical characterization of commercially available intravenous fat emulsions: estimation of average particle size, size distribution and surface potential using photon correlation spectroscopy [ J ]. Chem Pharm Bull, 1995,43 ( 8 ):1412 - 1415.
  • 10Levy MY, Schutze W, Fuhrer C, et al. Characterization of diazepam submicron emulsion interface: role of oleic acid [J]. J Microencapsulation, 1994,11(1) :79 -92.

共引文献19

同被引文献113

引证文献8

二级引证文献72

中国医药工业杂志
2007年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部